Arbutus Biopharma (ABUS) vs Annexon (ANNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Annexon (ANNX) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 8.3% versus a loss of 4.3%. Over five years, ABUS leads with a +4.7% price change compared with -81.6% for ANNX. Arbutus Biopharma is the larger company by market cap ($646.8 million vs $646.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | ANNX |
|---|---|---|
| Share price | $4.22 | $3.41 |
| Market cap | $646.82M | $646.46M |
| 1-day change | -1.63% | -5.28% |
| YTD return | -12.27% | -32.07% |
| 1-year return | -4.31% | +8.25% |
| 5-year return | +4.71% | -81.56% |
| P/E ratio (TTM) | 5.34 | — |
| EPS (TTM) | $0.79 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | — |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | $-206.69M |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $7.18 |
| 52-week low | $3.50 | $2.54 |
| Distance from 52-week high | -22.57% | -52.51% |
| Analyst consensus | none | none |
| Avg. price target upside | +27.96% | +352.49% |
| Average volume | 4.81M | 2.90M |
| Shares outstanding | 153.28M | 189.58M |
| Employees | 19 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed ABUS by 12.6 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
ABUS vs ANNX FAQ
Which is bigger, Arbutus Biopharma or Annexon?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $646.82M compared with $646.46M for Annexon (ANNX).
Which stock has performed better over the past year, ABUS or ANNX?
ANNX returned +8.25% over the past 12 months, compared with -4.31% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Annexon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.